Guggenheim Starts Coverage on Sagimet Biosciences with Buy Rating
Guggenheim analyst gives Sagimet Biosciences a Buy rating with $27 target, citing promising results for its FASN inhibitor in MASH and acne.
NOTRELOAD AI
FDA Grants Breakthrough Status to Zovegalisib for Advanced Breast Cancer
Relay Therapeutics' (RLAY) zovegalisib receives FDA Breakthrough Therapy designation for treating PIK3CA-mutant HR+/HER2- advanced breast cancer after CDK4/6 inhibitor treatment.
Pfizer Q4 2025: Strong Performance Despite COVID Decline
Pfizer beats Q4 estimates with $17.6B revenue as legacy drugs offset COVID sales drop. Obesity drug shows 12.3% weight loss. 2026 guidance reaffirmed.
PayPal CEO Replaced as Earnings Miss, Stock Tumbles
PayPal (PYPL) announces CEO change as Q4 earnings disappoint. HP's Enrique Lores to replace Alex Chriss. Shares drop 16% on weak retail spending and slowing branded checkout growth.
BofA Upgrades Sigma Lithium After Mining Restart
BofA analyst upgrades Sigma Lithium to Neutral as mining activities resume, reducing timeline risks but liquidity concerns remain.
Morgan Stanley Turns More Positive on Affirm Despite Stock Weakness
Morgan Stanley upgraded Affirm to Overweight, saying recent stock weakness offers a compelling risk/reward and long-term growth remains intact.